Compugen Reports Fourth Quarter and Full Year 2021 Results

Go back to Compugen Reports Fourth Quarter and Full Year 2021 Results

Compugen (CGEN) PT Lowered to $14 at Truist Securities

February 25, 2022 6:36 AM EST

Truist Securities analyst Asthika Goonewardene lowered the price target on Compugen (NASDAQ: CGEN) to $14.00 (from $20.00) while maintaining a Buy rating.

The analyst commented, "Following the EPS call and our discussion with mgmt, we are adjusting our model to reflect a slower route... More

Compugen (CGEN) PT Lowered to $14 at Stifel

February 24, 2022 12:17 PM EST

Stifel analyst Stephen Willey lowered the price target on Compugen (NASDAQ: CGEN) to $14.00 (from $20.00) while maintaining a Buy rating.

The analyst commented, "Management continues to make progress on the various dose expansion cohorts comprising the P1/2 development program evaluating various COM701-based combinations... More

Compugen (CGEN) Reports In-Line Q4 EPS

February 24, 2022 7:19 AM EST

Compugen (NASDAQ: CGEN) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10).

For earnings history and earnings-related data on Compugen (CGEN) click here.

... More